The role of cadmium and nickel in estrogen receptor signaling and breast cancer: Metalloestrogens or not?

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 30, Issue 3, 2012, Pages 189-224

  Aquino, Natalie B ^a   Sevigny, Mary B ^a   Sabangan, Jackielyn ^a   Louie, Maggie C ^a  

^a DOMINICAN UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; cadmium; estrogen receptor; metalloestrogen; nickel

Indexed keywords

BREAST CANCER; ENVIRONMENTAL RISK FACTOR; ESTROGEN RECEPTOR; HIGH CONCENTRATION; IN-VITRO; IN-VIVO; LOW-LEVEL EXPOSURE; METALLOESTROGEN; MULTIPLE CELLULAR FUNCTIONS; RISK FACTORS;

CADMIUM; HEAVY METALS; NICKEL; PATHOLOGY;

DISEASES;

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CADMIUM; DIETHYLSTILBESTROL; DIMETHYLBENZ[A]ANTHRACENE; DNA; ENDOCRINE DISRUPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; HEAVY METAL; METALLOESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE; NICKEL; TAMOXIFEN; UNCLASSIFIED DRUG;

BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CELL CYCLE; CHROMATIN; DNA BINDING; ENDOPLASMIC RETICULUM; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; LONG TERM EXPOSURE; METAL BINDING; NONHUMAN; POSTMENOPAUSE; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; URINE LEVEL;

BREAST NEOPLASMS; CADMIUM; CHROMATIN; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; NICKEL; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84866531506     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2012.705159     Document Type: Review

References (194)

1. American Cancer Society. Cancer facts & figures 2010. American Cancer Society, Atlanta; 2010.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78-85.
4. Nathanson KL, Wooster R, Weber BL. Breast cancer genetics: what we know and what we need. Nat Med. 2001;7(5):552-556.
5. Darbre PD. Metalloestrogens: an emerging class of inorganic xenoestrogens with potential to add to the oestrogenic burden of the human breast. J Appl Toxicol. 2006;26(3):191-197.
6. Antila E, Mussalo-Rauhamaa H, Kantola M, Atroshi F, Westermarck T. Association of cadmium with human breast cancer. Sci Total Environ. 1996;186(3):251-256.
7. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst. 2006;98(12): 869-873.
8. Julin B, Wolk A, Bergkvist L, Bottai M, Akesson A. Dietary cadmium exposure and risk of postmenopausal breast cancer: a population-based prospective cohort study. Cancer Res. 2012;72(6):1459-1466.
9. Islam E, Yang XE, He ZL, Mahmood Q. Assessing potential dietary toxicity of heavy metals in selected vegetables and food crops. J Zhejiang Univ Sci B. 2007;8(1):1-13.
10. Nikolic J, Sokolovic D. Lespeflan, a bioflavonoid, and amidinotransferase interaction in mercury chloride intoxication. Ren Fail. 2004;26(6):607-611.
11. Rollerova E, Urbancikova M. Intracellular estrogen receptors, their characterization and function (Review). Endocr Regul. 2000;34(4):203-218.
12. Misra UK, Gawdi G, Akabani G, Pizzo SV. Cadmium-induced DNA synthesis and cell proliferation in macrophages: the role of intracellular calcium and signal transduction mechanisms. Cell Signal. 2002;14(4):327-340.
13. Martin MB, Reiter R, Pham T et al. Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003;144(6):2425-2436.
14. Stoica A, Katzenellenbogen BS, Martin MB. Activation of estrogen receptor-alpha by the heavy metal cadmium. Mol Endocrinol. 2000;14(4):545-553.
15. Byrne C, Divekar SD, Storchan GB, Parodi DA, Martin MB. Cadmium - a metallohormone? Toxicol Appl Pharmacol. 2009;238(3):266-271.
16. Ikeda K, Inoue S. Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol. 2004;67(5):435-442.
17. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427-433.
18. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988;48(2):246-253.
19. Clark GM, McGuireWL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988;15(2 Suppl 1):20-25.
20. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004;6(6):240-245.
21. Masood S. Estrogen and progesterone receptors in cytology: a comprehensive review. Diagn Cytopathol. 1992;8(5):475-491.
22. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392(1):49-53.
23. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277(5331):1508-1510.
24. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140(12):5566-5578.
25. Huang HJ, Norris JD, McDonnell DP. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol. 2002;16(8):1778-1792.
26. DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005;19(2):362-378.
27. Wang W, Dong L, Saville B, Safe S. Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol. 1999;13(8):1373-1387.
28. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001;62:231-252.
29. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P. Estrogen receptor pathways to AP-1. Journal Steroid Biochem Molec Biol. 2000;74(5):311-317.
30. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol. 1997;11(11):1569-1580.
31. Cerillo G, Rees A, Manchanda N, Reilly C, Brogan I, White A, Needham M. The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. Journal Steroid Biochem Molec Biol. 1998;67(2):79-88.
32. Webb P, Nguyen P, Valentine C et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol. 1999;13(10):1672-1685.
33. Ray P, Ghosh SK, Zhang DH, Ray A. Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 1997;409(1):79-85.
34. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001;11(5):339-352.
35. Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clinical cancer research: an official journal of the Am Assoc Cancer Res. 2010;16(10):2702-2708.
36. Clarke R, Liu MC, Bouker KB et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003;22(47):7316-7339.
37. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer. 2004;11(3):537-551.
38. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology. 2001;142(9): 4120-4130.
39. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat. 2008;109(2):241-250.
40. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 2000;156(1):29-35.
41. Nair HB, Perla RP, Kirma NB, Krishnegowda NK, Ganapathy M, Rajhans R, Nair SS, Saikumar P, Vadlamudi RK, Tekmal RR. Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice. Horm Cancer. 2012;3(1-2):26-36.
42. Holst F, Stahl PR, Ruiz C et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007;39(5):655-660.
43. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HBEGF. Mol Endocrinol. 2000;14(10):1649-1660.
44. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715):1625-1630.
45. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146(2):624-632.
46. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun. 2006;346(3):904-910.
47. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res: an Official J Am Assoc Cancer Res. 2006;12(21):6359-6366.
48. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Ando S. The G protein-coupled receptor GPR30 mediates cfos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279(26):27008-27016.
49. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Molec Cellul Endocrinol. 2007; 265-266:138-142.
50. Stern D F. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000;2(3):176-183.
51. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40.
52. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. The EMBO J. 2009;28(5):523-532.
53. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 2010;70(14):6036-6046.
54. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9-18.
55. Brama M, Gnessi L, Basciani S et al. Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cellul Endocrinol. 2007;264(1-2):102-108.
56. Filardo EJ, Quinn JA, Frackelton AR, Jr., Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16(1):70-84.
57. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogenactivated protein kinase in human breast cancer. J Clin Invest. 1997;99(7):1478-1483.
58. Teng J, Wang ZY, Prossnitz ER, Bjorling DE. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology. 2008;149(8):4024-4034.
59. Wang C, Dehghani B, Magrisso IJ et al. GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol. 2008;22(3):636-648.
60. Ariazi EA, Brailoiu E, Yerrum S et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70(3):1184-1194.
61. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cellul Endocrinol. 2009;308(1-2):32-38.
62. International Programme on Chemical Safety. Cadmium. Geneva, World Health Organization, International Programme on Chemical Safety. Environmental Health Criteria. 134; 1992.
63. International Programme on Chemical Safety. Cadmium - Environmental aspects. Geneva, World Health Organization, International Programme on Chemical Safety Environmental Health Criteria. 135; 1992.
64. Hayes R B. The carcinogenicity of metals in humans. Cancer Causes Control. 1997;8(3):371-385.
65. International Programme on Chemical Safety. Nickel. Geneva, World Health Organization, International Programme on Chemical Safety. Environmental Health Criteria. 108; 1991.
66. Nielsen GD, Soderberg U, Jorgensen PJ, Templeton DM, Rasmussen SN, Andersen KE, Grandjean P. Absorption and retention of nickel from drinking water in relation to food intake and nickel sensitivity. Toxicol Appl Pharmacol. 1999;154(1): 67-75.
67. World Health Organization (WHO) Guidelines for Drinking-water Quality. Nickel in Drinking-water. http://www.who.int/water sanitation health/gdwqrevision/nickel2ndadd.pdf.
68. International Agency for Research on Cancer. Cadmium and cadmium compounds. IARC Monogr Eval Carcinog Risk Chem Man. 1976;11:39-74.
69. International Agency for Research on Cancer. Cadmium and cadmium compounds. IARC Monogr Eval Carcinog Risks Hum. 1993;58:119-237.
70. International Agency for Research on Cancer. Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. Working Group views and expert opinions, Lyon, 9-16 February 1993. IARC Monogr Eval Carcinog Risks Hum. 1993; 58:1-415.
71. US National Toxicology Program. Cadmium and cadmium compounds. Rep Carcinog. 2002;10:42-44.
72. US National Toxicology Program. Cadmium and cadmium compounds. Rep Carcinog. 2011;12:80-83.
73. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med (Lond). 2002;52(3):157-164.
74. Waalkes MP, Rehm S, Cherian MG. Repeated cadmium exposures enhance the malignant progression of ensuing tumors in rats. Toxicol Sci. 2000;54(1):110-120.
75. Waalkes MP, Anver MR, Diwan BA. Chronic toxic and carcinogenic effects of oral cadmium in the Noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes. J Toxicol Environ Health A. 1999;58(4):199-214.
76. Choe SY, Kim SJ, Kim HG, Lee JH, Choi Y, Lee H, Kim Y. Evaluation of estrogenicity of major heavy metals. Sci Total Environ. 2003;312(1-3):15-21.
77. Strumylaite L,Mechonosina K, Tamasauskas S. Environmental factors and breast cancer. Medicina (Kaunas). 2010;46(12):867-873.
78. Ionescu JG, Novotny J, Stejskal V, Latsch A, Blaurock-Busch E, Eisenmann-Klein M. Increased levels of transition metals in breast cancer tissue. Neuro Endocrinol Lett. 2006;27 (Suppl 1):36-39.
79. Strumylaite L, Bogusevicius A, Ryselis S, Pranys D, Poskiene L, Kregzdyte R, Abdrachmanovas O, Asadauskaite R.;[Association between cadmium and breast cancer]. Medicina (Kaunas). 2008;44(6):415-420.
80. Agency for Toxic Substances and Disease Registry. Toxicological profile for cadmium. US Department of Health and Human Services. http://www.atsdr.cdc. gov/toxprofiles/tp5-p.pdf.
81. Beyersmann D. Effects of carcinogenic metals on gene expression. Toxicology Lett. 2002;127(1-3):63-68.
82. International Agency for Research on Cancer. Nickel and nickel compounds. IARC Monogr Eval Carcinog Risk Chem Man. 1976;11:75-112.
83. International Agency for Research on Cancer. Chromium, nickel and welding. IARC Monogr Eval Carcinog Risks Hum. 1990;49:1-648.
84. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984;44(11):5390- 5394.
85. Johnson MD, Kenney N, Stoica A et al. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nat Med. 2003;9(8):1081-1084.
86. Jin T, Lu J, Nordberg M. Toxicokinetics and biochemistry of cadmium with special emphasis on the role of metallothionein. Neurotoxicology. 1998;19(4-5):529-535.
87. Nawrot T, Plusquin M, Hogervorst J, Roels HA, Celis H, Thijs L, Vangronsveld J, Van Hecke E, Staessen JA. Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncol. 2006;7(2):119-126.
88. Amzal B, Julin B, Vahter M, Wolk A, Johanson G, Akesson A. Population toxicokinetic modeling of cadmium for health risk assessment. Environ Health Perspect. 2009;117(8):1293-1301.
89. Benbrahim-Tallaa L, Tokar EJ, Diwan BA, Dill AL, Coppin JF, Waalkes MP. Cadmium malignantly transforms normal human breast epithelial cells into a basal-like phenotype. Environ Health Perspect. 2009;117(12):1847-1852.
90. Hofer N, Diel P, Wittsiepe J, Wilhelm M, Degen GH. Dose- and route-dependent hormonal activity of the metalloestrogen cadmium in the rat uterus. Toxicology Lett. 2009;191(2-3):123-131.
91. Ali I, Penttinen-Damdimopoulou PE, Makela SI, Berglund M, Stenius U, Akesson A, Hakansson H, Halldin K. Estrogen-like effects of cadmium in vivo do not appear to be mediated via the classical estrogen receptor transcriptional pathway. Environ Health Perspect. 2010;118(10):1389-1394.
92. Alonso-Gonzalez C, Gonzalez A, Mazarrasa O, Guezmes A, Sanchez-Mateos S, Martinez-Campa C, Cos S, Sanchez-Barcelo EJ,Mediavilla MD.Melatonin prevents the estrogenic effects of sub-chronic administration of cadmium on mice mammary glands and uterus. J Pineal Res. 2007;42(4):403-410.
93. Garcia-Morales P, Saceda M, Kenney N, Kim N, Salomon DS, Gottardis MM, Solomon HB, Sholler PF, Jordan VC, Martin MB. Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem. 1994;269(24):16896-16901.
94. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6(11):838-849.
95. Predki PF, Sarkar B. Effect of replacement of "zinc finger" zinc on estrogen receptor DNA interactions. J Biol Chem. 1992;267(9):5842-5846.
96. Siewit CL, Gengler B, Vegas E, Puckett R, Louie MC. Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERalpha and c-Jun. Mol Endocrinol. 2010;24(5):981-992.
97. Sun X, Fontaine JM, Bartl I, Behnam B, Welsh MJ, Benndorf R. Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells. Cell Stress Chaperones. 2007;12(4): 307-319.
98. Yu X, Filardo EJ, Shaikh ZA. The membrane estrogen receptor GPR30 mediates cadmium-induced proliferation of breast cancer cells. Toxicol Appl Pharmacol. 2010;245(1):83-90.
99. Liu Z, Yu X, Shaikh ZA. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol. 2008;228(3):286-294.
100. Fell GS, Ottaway JM, Hussein FE. Application of blood cadmium analysis to industry using an atomic fluorescence method. Br J Ind Med. 1977;34(2):106-109.
101. Lau TJ, Hackett RL, Sunderman FW, Jr. The carcinogenicity of intravenous nickel carbonyl in rats. Cancer Res. 1972;32(10):2253-2258.
102. Dunnick JK, Elwell MR, Radovsky AE, Benson JM, Hahn FF, Nikula KJ, Barr EB, Hobbs CH. Comparative carcinogenic effects of nickel subsulfide, nickel oxide, or nickel sulfate hexahydrate chronic exposures in the lung. Cancer Res. 1995;55(22):5251-5256.
103. International Agency for Research on Cancer. Cancer monographs on the evaluation of the carcinogenic risk of chemicals to humans: chromium, nickel and welding. Internation Agency Res Cancer. 1990;48:1-648.
104. Hueper W C. Experimental studies in metal cancerigenesis. IX. Pulmonary lesions in guinea pigs and rats exposed to prolonged inhalation of powdered metallic nickel. AMA Arch Pathol. 1958;65(6):600-607.
105. Ivankovic S, Zeller WJ, Komitowski D, Edler L, Lehman E, Frohlich N. Carcinogenesis of nickel alloys in the hamster following intratracheal instillation. Schriftenreihe der Bundesanstalt f ̈ur Arbeitsschutz, Dortmund, 1988:1-58.
106. Salnikow K, An WG, Melillo G, Blagosklonny MV, Costa M. Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis. 1999;20(9):1819-1823.
107. Salnikow K, Davidson T, Costa M. The role of hypoxia-inducible signaling pathway in nickel carcinogenesis. Environmental Health Perspect. 2002;110 (Suppl 5):831-834.
108. Tchou-Wong KM, Kiok K, Tang Z, Kluz T, Arita A, Smith PR, Brown S, Costa M. Effects of nickel treatment on H3K4 trimethylation and gene expression. PLoS One. 2011;6(3):e17728.
109. Kawata K, Shimazaki R, Okabe S. Comparison of gene expression profiles in HepG2 cells exposed to arsenic, cadmium, nickel, and three model carcinogens for investigating the mechanisms of metal carcinogenesis. Environ Mol Mutagen. 2009;50(1):46-59.
110. Kowara R, Karaczyn A, Cheng RY, Salnikow K, Kasprzak KS. Microarray analysis of altered gene expression in murine fibroblasts transformed by nickel(II) to nickel(II)-resistant malignant phenotype. Toxicol Appl Pharmacol. 2005;205(1): 1-10.
111. Ding J, He G, Gong W et al. Effects of nickel on cyclin expression, cell cycle progression and cell proliferation in human pulmonary cells. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1720-1729.
112. Ouyang W, Zhang D, Li J, Verma UN, Costa M, Huang C. Soluble and insoluble nickel compounds exert a differential inhibitory effect on cell growth through IKKalpha-dependent cyclin D1 down-regulation. J Cell Physiol. 2009;218(1):205-214.
113. Lu X, Bao X, Huang Y, Qu Y, Lu H, Lu Z. Mechanisms of cytotoxicity of nickel ions based on gene expression profiles. Biomaterials. 2009;30(2):141-148.
114. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995;1(12):1257-1260.
115. Foulkes WD, Brunet JS, Stefansson IM et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830-835.
116. Alao J P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.
117. Nesatyy VJ, Rutishauser BV, Eggen RI, Suter MJ. Identification of the estrogen receptor Cd-binding sites by chemical modification. Analyst. 2005;130(7):1087-1097.
118. Satofuka H, Fukui T, Takagi M, Atomi H, Imanaka T. Metal-binding properties of phytochelatin-related peptides. J Inorg Biochem. 2001;86(2-3):595-602.
119. Maier T, Yu C, Kullertz G, Clemens S. Localization and functional characterization of metal-binding sites in phytochelatin synthases. Planta. 2003;218(2):300-308.
120. Deegan BJ, Bona AM, Bhat V, Mikles DC, McDonald CB, Seldeen KL, Farooq A. Structural and thermodynamic consequences of the replacement of zinc with environmental metals on estrogen receptor alpha-DNA interactions. J Mol Recognit. 2011;24(6):1007-1017.
121. Low LY, Hernandez H, Robinson CV, O'Brien R, Grossmann JG, Ladbury JE, Luisi B. Metal-dependent folding and stability of nuclear hormone receptor DNAbinding domains. J Mol Biol. 2002;319(1):87-106.
122. Freedman LP, Luisi BF, Korszun ZR, Basavappa R, Sigler PB, Yamamoto KR. The function and structure of the metal coordination sites within the glucocorticoid receptor DNA binding domain. Nature. 1988;334(6182):543-546.
123. Predki PF, Sarkar B. Metal replacement in "zinc finger" and its effect on DNA binding. Environ Health Perspect. 1994;102 (Suppl 3):195-198.
124. Ke Q, Davidson T, Chen H, Kluz T, Costa M. Alterations of histone modifications and transgene silencing by nickel chloride. Carcinogenesis. 2006;27(7):1481-1488.
125. Ke Q, Ellen TP, Costa M. Nickel compounds induce histone ubiquitination by inhibiting histone deubiquitinating enzyme activity. Toxicol Appl Pharmacol. 2008;228(2):190-199.
126. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K, Zhitkovich A, Christie NT, Costa M. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol. 1995;15(5):2547-2557.
127. Chen H, Ke Q, Kluz T, Yan Y, Costa M. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol. 2006;26(10): 3728-3737.
128. Ellen TP, Kluz T, Harder ME, Xiong J, Costa M. Heterochromatinization as a potential mechanism of nickel-induced carcinogenesis. Biochemistry. 2009;48(21):4626-4632.
129. Arita A, Costa M. Epigenetics in metal carcinogenesis: nickel, arsenic, chromium and cadmium. Metallomics. 2009;1(3):222-228.
130. Lu H, Shi X, Costa M, Huang C. Carcinogenic effect of nickel compounds. Mol Cell Biochem. 2005;279(1-2):45-67.
131. Karaczyn AA, Golebiowski F, Kasprzak KS. Ni(II) affects ubiquitination of core histones H2B and H2A. Exp Cell Res. 2006;312(17):3252-3259.
132. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 2002;3(3):224-229.
133. Chen H, Tini M, Evans RM. HATs on and beyond chromatin. Curr Opin Cell Biol. 2001;13(2):218-224.
134. Ellen TP, Kluz T, Harder ME, Xiong J, Costa M. Heterochromatinization as a potential mechanism of nickel-induced carcinogenesis. Biochemistry. 2009.
135. Krogan NJ, Kim M, Tong A et al. Methylation of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol. 2003;23(12):4207-4218.
136. Schubeler D, MacAlpine DM, Scalzo D et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 2004;18(11):1263-1271.
137. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006;66(7):3541-3549.
138. Kasprzak KS, Bal W, Karaczyn AA. The role of chromatin damage in nickel-induced carcinogenesis. A review of recent developments. J Environ Monit. 2003;5(2):183-187.
139. Govindarajan B, Klafter R,MillerMS, Mansur C, MizeskoM, Bai X, LaMontagne K, Jr., Arbiser JL. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med. 2002;8(1):1-8.
140. Kowara R, Salnikow K, Diwan BA, Bare RM, Waalkes MP, Kasprzak KS. Reduced Fhit protein expression in nickel-transformed mouse cells and in nickel-induced murine sarcomas. Mol Cell Biochem. 2004;255(1-2):195-202.
141. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
142. Wei LH, Torng PL, Hsiao SM, Jeng YM, Chen MW, Chen CA. Histone deacetylase 6 regulates estrogen receptor alpha in uterine leiomyoma. Reprod Sci. 2011;18(8):755-762.
143. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer. 2003;107(3):353-358.
144. Moggs JG, Orphanides G. Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep. 2001;2(9):775-781.
145. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res. 2003;286(2):355-365.
146. Huang D, Zhang Y, Qi Y, Chen C, Ji W. Global DNA hypomethylation, rather than reactive oxygen species (ROS), a potential facilitator of cadmium-stimulated K562 cell proliferation. Toxicology Lett. 2008;179(1):43-47.
147. Evans H J. Neoplasia and cytogenetic abnormalities. Basic Life Sci. 1985;36:165-178.
148. Oshimura M, Barrett JC. Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. EnvironMutagen. 1986;8(1):129-159.
149. Hill R P. Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev. 1990;9(2):137-147.
150. Cheng KC, Loeb LA. Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res. 1993;60:121-156.
151. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A. 1998;95(23):13692-13697.
152. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999;9(12):M57-60.
153. Li R, Yerganian G, Duesberg P, Kraemer A, Willer A, Rausch C, Hehlmann R. Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc Natl Acad Sci U S A. 1997;94(26):14506-14511.
154. Seoane A, C FD. Contribution to the validation of the anaphase-telophase test: aneugenic and clastogenic effects of cadmium sulfate, potassium dichromate and nickel chloride in Chinese hamster ovary cells. Genet Mol Biol. 1999;22: 551-555.
155. Andersen O. Evaluation of the spindle-inhibiting effect of Ni++ by quantitation of chromosomal super-contraction. Res Commun Chem Pathol Pharmacol. 1985;50(3):379-386.
156. Coogan TP, Bare RM, Waalkes MP. Cadmium-induced DNA strand damage in cultured liver cells: reduction in cadmium genotoxicity following zinc pretreatment. Toxicol Appl Pharmacol. 1992;113(2):227-233.
157. Parry JM, Sors A. The detection and assessment of the aneugenic potential of environmental chemicals: the European Community Aneuploidy Project. Mutat Res. 1993;287(1):3-15.
158. Vega L, Gonsebatt ME, Ostrosky-Wegman P. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat Res. 1995;334(3):365-373.
159. Seoane AI, Dulout FN. Genotoxic ability of cadmium, chromium and nickel salts studied by kinetochore staining in the cytokinesis-blocked micronucleus assay. Mutat Res. 2001;490(2):99-106.
160. Epe B, Harttig U, Stopper H, Metzler M. Covalent binding of reactive estrogen metabolites to microtubular protein as a possible mechanism of aneuploidy induction and neoplastic cell transformation. Environm Health Perspect. 1990;88: 123-127.
161. Hontz AE, Li SA, Lingle WL, Negron V, Bruzek A, Salisbury JL, Li JJ. Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res. 2007;67(7):2957-2963.
162. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22(4):451-464.
163. Bischoff JR, Anderson L, Zhu Y et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. The EMBO J. 1998;17(11):3052-3065.
164. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res. 1998;58(21):4811-4816.
165. International Agency for Research on Cancer. Arsenic and arsenic compounds. IARC Monogr Eval Carcinog Risk Chem Hum. 1980;23:39-141.
166. International Agency for Research on Cancer. Some metals and metallic compounds. IARC Monogr Eval Carcinog Risk Chem Hum. 1980;23:1-415.
167. Hinwood AL, Sim MR, Jolley D, de Klerk N, Bastone EB, Gerostamoulos J, Drummer OH. Risk factors for increased urinary inorganic arsenic concentrations from low arsenic concentrations in drinking water. Int J Environ Health Res. 2003;13(3):271-284.
168. Hinwood AL, Sim MR, Jolley D, de Klerk N, Bastone EB, Gerostamoulos J, Drummer OH. Hair and toenail arsenic concentrations of residents living in areas with high environmental arsenic concentrations. Environ Health Perspect. 2003;111(2):187-193.
169. Chatterjee A, Chatterji U. Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod Biol Endocrinol. 2010;8:80.
170. Davey JC, Bodwell JE, Gosse JA, Hamilton JW. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci. 2007;98(1):75-86.
171. Romanowicz-Makowska H, Forma E, Brys M, Krajewska WM, Smolarz B. Concentration of cadmium, nickel and aluminium in female breast cancer. Pol J Pathol. 2011;62(4):257-261.
172. Benderli Cihan Y, Sozen S, Ozturk Yildirim S. Trace elements and heavy metals in hair of stage III breast cancer patients. Biol Trace Elem Res. 2011;144(1-3):360-379.
173. Strumylaite L, Bogusevicius A, Abdrachmanovas O, Baranauskiene D, Kregzdyte R, Pranys D, Poskiene L. Cadmium concentration in biological media of breast cancer patients. Breast Cancer Res Treat. 2011;125(2):511-517.
174. Anderson LM, Diwan BA, Fear NT, Roman E. Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect. 2000;108 (Suppl 3):573-594.
175. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003;111(4):389-394.
176. Hilakivi-Clarke L. Estrogens, BRCA1, and breast cancer. Cancer Res. 2000;60(18):4993-5001.
177. Weiss HA, Potischman NA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, Schoenberg JB. Prenatal and perinatal risk factors for breast cancer in young women. Epidemiology. 1997;8(2):181-187.
178. Glasier A. HRT and breast cancer. Women's Health Med. 2006;3(1):15-17.
179. Gustafsson J A. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J Endocrinol. 1999;163(3):379-383.
180. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nature Rev Cancer. 2011;11(8):597-608.
181. Prossnitz E R, Arterburn J B, Smith H O, Oprea T I, Sklar L A, Hathaway H J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Ann Rev Physiol. 2008;70:165-190.
182. Luparello C, Longo A, Vetrano M. Exposure to cadmium chloride influences astrocyte-elevated gene-1 (AEG-1) expression in MDA-MB231 human breast cancer cells. Biochimie. 2012;94(1):207-213.
183. Casano C, Agnello M, Sirchia R, Luparello C. Cadmium effects on p38/MAPK isoforms in MDA-MB231 breast cancer cells. Biometals: an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine. 2010;23(1):83-92.
184. Cannino G, Ferruggia E, Luparello C, Rinaldi AM. Effects of cadmium chloride on some mitochondria-related activity and gene expression of human MDA-MB231 breast tumor cells. J Inorg Biochem. 2008;102(8):1668-1676.
185. Sirchia R, Longo A, Luparello C. Cadmium regulation of apoptotic and stress response genes in tumoral and immortalized epithelial cells of the human breast. Biochimie. 2008;90(10):1578-1590.
186. Sirchia R, Luparello C. Short-term exposure to cadmium affects the expression of stress response and apoptosis-related genes in immortalized epithelial cells from the human breast. Toxicology in vitro: an International Journal Published in Association with BIBRA. 2009;23(5):943-949.
187. Pan J, Chang Q,Wang X, Son Y, Zhang Z, Chen G, Luo J, Bi Y, Chen F, Shi X. Reactive oxygen species-activated Akt/ASK1/p38 signaling pathway in nickel compoundinduced apoptosis in BEAS 2B cells. Chemical Res Toxicol. 2010;23(3):568-577.
188. Cai T, Li X, Ding J, Luo W, Li J, Huang C. A cross-talk between NFAT and NF-kappaB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells. Current Cancer Drug Targets. 2011;11(5):548-559.
189. Hu W, Feng Z, Tang MS. Nickel (II) enhances benzooo[a]pyrene diol epoxideinduced mutagenesis through inhibition of nucleotide excision repair in human cells: a possible mechanism for nickel (II)-induced carcinogenesis. Carcinogenesis. 2004, 25(3):455-462.
190. Lin X, Dowjat WK, Costa M. Nickel-induced transformation of human cells causes loss of the phosphorylation of the retinoblastoma protein. Cancer Res. 1994;54(10):2751-2754.
191. Zhang Z, Li W, Cheng S et al. Nickel-induced down-regulation of DeltaNp63 and its role in the proliferation of keratinocytes. Toxicol Appl Pharmacol. 2011;253(3):235-243.
192. M'Bemba-Meka P, Lemieux N, Chakrabarti SK. Nickel compound-induced DNA single-strand breaks in chromosomal and nuclear chromatin in human blood lymphocytes in vitro: role of oxidative stress and intracellular calcium. Mutation Res. 2005;586(2):124-137.
193. Zang Y, Odwin-Dacosta S, Yager JD. Effects of cadmium on estrogen receptor mediated signaling and estrogen induced DNA synthesis in T47D human breast cancer cells. Toxicology Lett. 2009;184(2):134-138.
194. Sinha Roy S, Mukherjee S, Mukhopadhyay S, Das SK. Differential effect of cadmium on cholinephosphotransferase activity in normal and cancerous human mammary epithelial cell lines. Molecul Cancer Therapeut. 2004;3(2):199-204.